At­las-backed biotech fo­cused on Hunt­ing­ton's dis­ease shuts down less than three years af­ter launch

An At­las-found­ed biotech qui­et­ly shut down this week, with the CEO post­ing on­ly a short state­ment on LinkedIn to an­nounce the move.

Triplet Ther­a­peu­tics is no longer op­er­a­tional, chief ex­ec Nes­san Berming­ham said on the so­cial me­dia site Tues­day, less than three years af­ter it launched. In De­cem­ber 2019, Triplet de­buted with a $59 mil­lion Se­ries A, nab­bing cash from At­las, MPM Cap­i­tal and Pfiz­er Ven­tures in an ef­fort to de­vel­op an­ti­sense drugs for Hunt­ing­ton’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER